

XXVIII IFSO World Congress

9-12 September 2025 | Santiago, Chile



SADI-S: Medium-Long Term Results:
What the Evidence Tells?

IFSO 2025 Santiago

Combined Therapies, The Dawn of a New Era

ifso2025.org



XXVIII IFSO World Congress

9-12 September 2025
Santiago, Chile

Nothing to disclose


The birth of SADI-S



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



2007



2009





XXVIII IFSO World Congress


9-12 September 2025
Santiago, Chile

OBESITY SURGERY

The Journal of Metabolic Surgery and Allied Care

Sánchez-Pernaute A, et al. (2010)

Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). One to three-year follow-up. *Obes Surg.* 2010;20(12):1720-6. DOI: 10.1007/s11695-010-0247-3.



DESIGN

- Retrospective series, **n=50** (18 men / 32 women)
- **Mean BMI:** 44 kg/m²
- **Follow-up:** 3 years

EFFICACY (WEIGHT & METABOLIC)

- **%EWL 94.7% at 1 year, maintained** at years 2–3
- **Diabetes: complete remission in all diabetic patients by 6 months** (off medications)

SAFETY & NUTRITION


- **Major complications:** 2 staple-line leaks, 1 subphrenic abscess
- **Mild anemia:** 10% (year 1)
- **Low albumin:** 8% (year 1) → **normalized** by year 3

KEY TAKE-HOME

- **Safe and highly effective** for weight loss and metabolic control at 1–3 years, with **manageable nutritional events** under follow-up

SADI-S

Sánchez-Pernaute A, et al. (2010)
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). One to three-year follow-up. *Obes Surg.* 2010;20(12):1720-6. DOI: 10.1007/s11695-010-0247-3.




The birth of SADI-S



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?




2007



2009

50 CASES



2013



200 CM → 250 CM



ifso2025.org

The SADI-S Spreads Worldwide



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?

SADI-S expand globally

2013


300 cm, 40fr



300 cm, 36fr





150-200 cm, 45fr



200-300 cm, 38fr



250 cm, 34fr



Severe Obesity
BMI>50

ifso2025.org

Validation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?





XXVIII IFSO World Congress

9-12 September 2025
Santiago, Chile



ELSEVIER



CrossMark

SURGERY FOR OBESITY
AND RELATED DISEASES

Surgery for Obesity and Related Diseases 12 (2016) 944–945

ASMBS Guidelines/Statements

American Society for Metabolic and Bariatric Surgery statement on single-anastomosis duodenal switch

Julie Kim, M.D., F.A.C.S., F.A.S.M.B.S.,* on behalf of the American Society for Metabolic and
Bariatric Surgery Clinical Issues Committee

Department of General Surgery, Tufts Medical Center, Boston, Massachusetts

Received May 3, 2016; accepted May 3, 2016



ifso2025.org



XXVIII IFSO World Congress

9-12 September 2025
Santiago, Chile

EVIDENCE AT THAT TIME

- Only 4 published studies, total of 222 patients, follow-up 18 months–5 years.
- Most data from a **single institution**.
- **No randomized or prospective** comparative trials.
- **Insufficient evidence on long-term** safety, efficacy, and durability

OFFICIAL ASMBS RECOMMENDATIONS (2016)

- SADI-S is considered **investigational (experimental)**.
- Should be **performed** only under **study protocols**



Validation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?





XXVII IFSO
World Congress
9-12 September 2025
Santiago, Chile

**SURGERY FOR OBESITY
AND RELATED DISEASES**


Review article

**The single anastomosis duodenal switch modifications: a review of the
current literature on outcomes**

Philippe Topart, M.D.*, Guillaume Becouarn, M.D.

Société de Chirurgie Viscérale, Clinique de l'Anjou, Angers, France

Received December 20, 2016; accepted April 18, 2017



DESIGN

- Narrative review, **19 studies 1,041 patients, 304 SADI-S, 667 SIPS, 70 SADJB-SG**
- **Average Follow-up: 5 years**

EFFICACY (WEIGHT)

- **1 year: %EWL ~78% (range 61–87%); %TWL ~37%.**
- **2 years: %TWL ~39%.**
- **5 years: %EWL >70% (in most series) %TWL ~37%**
- **BMI reduction: Mean postoperative BMI reached ~27 kg/m² at 5 years in long-term series**

EFFICACY (METABOLIC)


- **Diabetes remission/improvement: 60–86% at 1 year.**
- **At 5 years: 70% of diabetic patients were off medication.**
- **Hypertension: Improvement in 42–96% of patients within the first year.**
- **Sleep apnea: Remission rates up to 97% at 1 year.**

SADI-S

Review article

The single anastomosis duodenal switch modifications: a review of the current literature on outcomes

Philippe Topart, M.D.*, Guillaume Becouarn, M.D.
Société de Chirurgie Viscérale, Clinique de l'Anjou, Angers, France
Received December 20, 2016; accepted April 18, 2017



SAFETY

- **Early complications: 7.3% average** (range 1.6–14%).
- **Reoperations: <2% in most series**; one report showed 11% at 30 days.
- **Mortality: None reported.**

NUTRITION

- **Protein malnutrition: 7–29%** depending on the series.
- **Vitamin deficiencies:**
 1. **Vitamin A: up to 45–53%.**
 2. **Vitamin D: 42–46%.**
 3. **Vitamin B12: <10% in most reports.**
 4. **Other deficits: zinc, selenium, secondary hyperparathyroidism** in up to **54%** in some series.
- **Revision rate** (for malnutrition/diarrhea): **increased from 2% at 2 years to 7% at 5 year.**


SADLES

Review article

The single anastomosis duodenal switch modifications: a review of the current literature on outcomes

Philippe Topart, M.D.*, Guillaume Becouarn, M.D.

Société de Chirurgie Viscérale, Clinique de l'Anjou, Angers, France
Received December 20, 2016; accepted April 18, 2017




Validation



**XXVIII IFSO
World Congress**

**9-12 September 2025
Santiago, Chile**

WHAT EVIDENCE TELLS?



Validation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?

1st

Multicenter Cohort



Surgery for Obesity and Related Diseases 14 (2018) 594–602

SURGERY FOR OBESITY
AND RELATED DISEASES

Original article

The incidence of complications associated with loop duodeno-ileostomy after single-anastomosis duodenal switch procedures among 1328 patients: a multicenter experience

Amit Surve, M.D.^a, Daniel Cottam, M.D.^{a,*}, Andres Sanchez-Pernaute, M.D., Ph.D.^b, Antonio Torres, M.D.^b, Joshua Roller, M.D.^c, Yong Kwon, M.D.^c, Joshua Mourot, M.D.^c, Bleu Schniederjan, M.D., F.A.C.S., F.A.S.M.B.S.^d, Bo Neichoy, M.D.^d, Paul Enochs, M.D., F.A.C.S., F.A.S.M.B.S.^e, Michael Tyner, M.D., F.A.M.B.S.^e, Jon Bruce, M.D., F.A.C.S., F.A.S.M.B.S.^e, Scott Bovard, M.D., F.A.C.S., F.A.S.M.B.S.^e, Mitchell Roslin, M.D.^f, Muhammad Jawad, M.D., F.A.C.S.^g, Andre Teixeira, M.D.^g, Myur Srikanth, M.D., F.A.C.S., F.A.S.M.B.S.^h, Jason Free, M.B.B.S., B.V.Sc, F.R.A.C.S.ⁱ, Hinali Zaveri, M.D.^a, David Pilati, M.D., F.A.C.S.^e, Jamie Bull, S.T., C.R.C., B.S.N.C.^e, LeGrand Belnap, M.D.^a, Christina Richards, M.D., F.A.C.S.^a, Walter Medlin, M.D., F.A.C.S.^a, Rena Moon, M.D.^g, Austin Cottam^a, Sarah Sabrudin, M.D.^f, Samuel Cottam^a, Aneesh Dhorepatil, M.B.B.S.^a

Centers: 9,
Leaks: 0.6% (9/1,328)
Strictures: 0.3% (5/1,328)
Ulcers: 0.1%
Bile reflux: 0.1%
Obstruction: 0%
Mortality: 0% .

2018



Validation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?

1st
Multicenter Cohort

Centers:9
Leaks: 0.6% (9/1,328)
Strictures: 0.3% (5/1,328)
Ulcers: 0.1%
Bile reflux: 0.1%
Obstruction: 0%
Mortality: 0% .

2018



1st
Sistematic Review

[1] S. Shoar, L. Poliakin, R. Rubenstein, and A. A. Saber, "Single anastomosis duodeno-ileal switch (SADIS): a systematic review of efficacy and safety," *Obes Surg.*, vol. 28, no. 1, pp. 104–113, 2018. doi: [10.1007/s11695-017-2838-8](https://doi.org/10.1007/s11695-017-2838-8)

Validation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Position Statement

1st Multicenter Cohort



2018



1st Systematic Review

Validation



XXVIII IFSO
World Congress
9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?

1st

Multicenter Cohort



Position Statement

- **Safe and efficacious** for obesity and metabolic disease.
- Lack of **long-term data**.
- Need for **randomized controlled trials (RCTs)**.
- **Potential nutritional risks** require close monitoring.

2018



1st

Systematic Review

> *Obes Surg.* 2018 May;28(5):1207-1216. doi: 10.1007/s11695-018-3201-4.

Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy/One Anastomosis Duodenal Switch (SADI-S/OADS) IFSO Position Statement

Wendy A Brown ¹, Geraldine Ooi ², Kelvin Higa ², Jacques Himpens ², Antonio Torres ²; IFSO-appointed task force reviewing the literature on SADI-S/OADS

Affiliations + expand

PMID: 29572769 DOI: 10.1007/s11695-018-3201-4

Consolidation

WHAT EVIDENCE TELLS?



Consolidation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Surgery for Obesity and Related Diseases 16 (2020) 825–830

SURGERY FOR OBESITY
AND RELATED DISEASES

ASMBS Guidelines/Statements

American Society for Metabolic and Bariatric Surgery updated statement on single-anastomosis duodenal switch

Kara Kallies, M.S. *, Ann M. Rogers, M.D., F.A.C.S., F.A.S.M.B.S., for the American Society
for Metabolic and Bariatric Surgery Clinical Issues Committee

Division of Minimally Invasive and Bariatric Surgery, Penn State Health, Hershey, Pennsylvania
Received 16 March 2020; accepted 16 March 2020

2020
Official Endorsment



Consolidation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Surgery for Obesity and Related Diseases 16 (2020) 825–830

SURGERY FOR OBESITY
AND RELATED DISEASES

ASMBS Guidelines/Statements

American Society for Metabolic and Bariatric Surgery updated statement on single-anastomosis duodenal switch

Kara Kallies, M.S.* , Ann M. Rogers, M.D., F.A.C.S., F.A.S.M.B.S., for the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee

Division of Minimally Invasive and Bariatric Surgery, Penn State Health, Hershey, Pennsylvania
Received 16 March 2020; accepted 16 March 2020

2020
Official Endorsment



- SADI-S moved from “investigational” (2016) to “accepted bariatric-metabolic procedure”.
- Weight loss & diabetes remission: **Comparable to classic DS.**
- Advantages over DS: **Shorter operative time, technically simpler, fewer internal hernias.**
- **Vs. RYGB: Similar weight loss, fewer marginal ulcers, less nausea, fewer endoscopies.**
- Early complications: **Low (1–5%).**
- Nutritional issues: Still present (protein, fat-soluble vitamins).
- Recommendation: Use **≥300 cm common channel + strict long-term nutritional follow-up.**

Consolidation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Position Statement Update 2021



2020 Official Endorsment



> *Obes Surg.* 2021 Jan;31(1):3-25. doi: 10.1007/s11695-020-05134-7. Epub 2021 Jan 6.

Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy/One Anastomosis Duodenal Switch (SADI-S/OADS) IFSO Position Statement-Update 2020

Wendy A Brown ¹, Guillermo Ponce de Leon Ballesteros ², Geraldine Ooi ², Kelvin Higa ², Jacques Himpens ², Antonio Torres ², Scott Shikora ², Lilian Kow ², Miguel F Herrera ²; IFSO appointed task force reviewing the literature on SADI-S/OADS

Affiliations + expand

PMID: 33409979 DOI: 10.1007/s11695-020-05134-7

ifso2025.org

Consolidation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Position Statement Update 2021

- **Expanded analysis** including 93 studies, including long term results
- **Efficacy confirmed:** Sustained weight loss and strong T2DM remission also at mid/long-term follow-up
- **Safety:** Overall complication profile remained low, but nutritional risks emphasized.
- **Nutrition:** Clear acknowledgment of frequent deficiencies (fat-soluble vitamins, iron, albumin)

2020
Official Endorsment



> *Obes Surg.* 2021 Jan;31(1):3-25. doi: 10.1007/s11695-020-05134-7. Epub 2021 Jan 6.

Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy/One Anastomosis Duodenal Switch (SADI-S/OADS) IFSO Position Statement-Update 2020

Wendy A Brown ¹, Guillermo Ponce de Leon Ballesteros ², Geraldine Ooi ², Kelvin Higa ², Jacques Himpens ², Antonio Torres ², Scott Shikora ², Lilian Kow ², Miguel F Herrera ²; IFSO appointed task force reviewing the literature on SADI-S/OADS

Affiliations + expand

PMID: 33409979 DOI: 10.1007/s11695-020-05134-7

ifso2025.org

Consolidation



**XXVIII IFSO
World Congress**

**9-12 September 2025
Santiago, Chile**

WHAT EVIDENCE TELLS?



**Position Statement Update
2021**

**2020
Official Endorsment**



1st

**2022
Meta-analysis**

Consolidation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?

Meta-Analysis > [Obes Surg.](#) 2022 Apr;32(4):1049-1063. doi: 10.1007/s11695-021-05824-w.
Epub 2022 Jan 10.

Evaluation of Metabolic Outcomes Following SADI-S: a Systematic Review and Meta-analysis

Kevin Verhoeff¹, Valentin Mocanu², Aiden Zalasky³, Jerry Dang², Janice Y Kung⁴,
Noah J Switzer², Daniel W Birch⁵, Shahzeer Karmali⁵

Affiliations + expand

PMID: 35001254 DOI: [10.1007/s11695-021-05824-w](#)



Position Statement Update
2021

2020
Official Endorsment



1st

2022
Meta-analysis

- Compared: **SADI-S** vs other malabsorptive procedures (mainly **RYGB** and **BPD-DS**).
- **Findings:**
 1. Shorter **operative time** and **hospital stay** with SADI-S.
 2. Comparable perioperative **safety**, with trend toward **fewer** complications.
 3. Similar **weight loss** (~37% TWL).
 4. Comparable **diabetes** remission overall, but **higher remission than RYGB** in subgroup analysis.

[ifso2025.org](#)

Consolidation




XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Position Statement Update
2021



VS

Meta-Analysis
2023

- Hypertension resolution: **48%**
- Dyslipidemia resolution: **55%**
- Diabetes remission: **63%**
- Post-op diarrhea: **2%**
- EWL: **48%** (6 mo), **59%** (12 mo), **24%** (24 mo)
- Leak rate: **1%**
- **Conclusion:** SADI is **feasible, efficient, and safe** as a **revisional surgery after SG**, but **long-term nutritional outcomes need exploration.**

2020
Official Endorsment



1st

2022
Meta-analysis

VS

RNY

> [J Metab Bariatr Surg.](#) 2023 Dec;12(2):35-43. doi: 10.17476/jmbs.2023.12.2.35. Epub 2023 Nov 8.

Single Anastomosis Duodeno-Ileal Bypass (SADI) as a Second Step After Failed Sleeve Gastrectomy: Systematic Review and Meta-analysis

Karim Ataya ¹, Ayman Bsar ², Abdul Hafiz Al Tannir ², Al Moutuz Al Jaafareh ¹, Amir Rabih Al ³, George Abi Saad ⁴

ifso2025.org

Consolidation




XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Position Statement Update
2021



VS

Meta-Analysis
2023



2020
Official Endorsment



1st

2022
Meta-analysis

VS

RNY

2024
Position Statement
update



Consolidation



XXVIII IFSO
World Congress

9-12 September 2025
Santiago, Chile

WHAT EVIDENCE TELLS?



Position Statement Update
2021



VS
Meta-Analysis
2023



Randomized
Controlled Trial
2025

2020
Official Endorsment



2022
Meta-analysis



RNY

2024
Position Statement
update





XXVIII IFSO World Congress

9-12 September 2025
Santiago, Chile

THE LANCET

Randomized Controlled Trial > [Lancet](#). 2025 Aug 23;406(10505):846-859.

doi: [10.1016/S0140-6736\(25\)01070-0](#).

Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up

Maud Robert ¹, Tigran Poghosyan ², Nicolas Romain-Scelle ³, Sebastien Czernichow ⁴,
Dominique Delaunay ⁵, Adrien Sterkers ⁶, Litavan Khamphommala ⁶, Andrea Lazzati ⁷,
Claire Blanchard ⁸, Robert Caiazzo ⁹, François Pattou ¹⁰, Emmanuel Disse ¹¹;
SADISLEEVE Collaborative Group

DESIGN

- Randomized controlled trial: with **381 patients** (190 SADI-S; 191 RYGB)
- Inclusion: BMI ~46 kg/m²; 21% had prior sleeve gastrectomy; intention-to-treat analysis

PRIMARY OUTCOME: EXCESS WEIGHT LOSS (EWL) AT 2 YEARS

- **SADI-S: -76.0% (SD 26.7)**
- **RYGB: -68.1% (SD 28.7)**
- **Mean difference: -6.72% (95% CI -12.64 to -0.80), p = 0.026 → statistically significant superiority of SADI-S**

FINAL INTERPRETATION

SADI-S demonstrated superior weight loss at 2 years, with comparable safety compared to RYGB.

SADI-S

Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up

Maud Robert¹, Tigran Poghosyan², Nicolas Romain-Scelle³, Sébastien Czernichow⁴, Dominique Delaunay⁵, Adrien Sterkers⁶, Litavan Khamphommala⁶, Andrea Lazzati⁷, Claire Blanchard⁸, Robert Caiazzo⁹, François Pattou¹⁰, Emmanuel Disse¹¹; SADISLEEVE Collaborative Group

Conclusion



**XXVIII IFSO
World Congress**

**9-12 September 2025
Santiago, Chile**

WHAT EVIDENCE TELLS?

- **SADI-S has evolved from “experimental” to “accepted and endorsed” by both ASMBS and IFSO.**
- **Evidence now includes large cohorts, systematic reviews, meta-analyses, and the first RCT.**
- **Findings: Superior or comparable weight loss and metabolic outcomes vs RYGB and DS, with low surgical risk.**
- **Challenge: Nutritional deficiencies remain significant → lifelong monitoring and multidisciplinary care are mandatory.**

XXVIII IFSO World Congress

9-12 September 2025 | Santiago, Chile



GRACIAS

IFSO 2025 Santiago

Combined Therapies, The Dawn of a New Era



Dr. Christian Rdz

ifso2025.org